Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

RARE PHOTOS: 9 | Rare Historical Photos

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 18 strange trades.

Benzinga

If You Could Only Buy 1 Stock, This Would Be It

Leading pharma company AbbVie (ABBV) has been witnessing solid business growth, thanks to its lucrative product portfolio and robust financials. And given its record of stable dividend payments, it could be a wise investment now amid the volatile market backdrop. Keep reading….

StockNews.com

5 Stocks You'll Want in Your Corner if a Recession Hits

Growing fears over a potential recession due to high inflation and the Federal Reserve’s aggressive interest rate hikes should keep the stock market highly volatile in the upcoming months. However, investors could consider buying relatively stable and dividend-paying stocks Procter & Gamble (PG), AbbVie (ABBV), Abbott (ABT), Caterpillar (CAT), and…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Safe Dividend Stocks to Buy in the Second Half of 2022

The market outlook seems dismal ahead of the Fed’s anticipated July rate hike announcement. Amid rising recession fears, more investors prefer dividend stocks for stable income assurance. Moreover, with dividend payouts slated to increase, we think it could be wise to invest in quality dividend stocks Nucor (NUE), The Procter…

StockNews.com

4 Value Stocks That Still Profit During Times of Uncertainty

Ahead of the Fed’s July rate hike, markets seem volatile. Given the viability of value investing during such times, quality value stocks Intel (INTC), Micron Technology (MU), AbbVie (ABBV), and Cisco Systems (CSCO) could be solid picks to navigate a volatile environment. Keep reading….

StockNews.com

Ready to Retire? These 3 Stocks Could Help You Do It Earlier

Investors planning their retirement finances could benefit from investing in equities with stable return potential and consistent dividend payouts amid the current market volatility. On that front, investing in quality dividend-paying stocks Philip Morris (PM), Flowers Foods (FLO), and AbbVie (ABBV) could be rewarding. Read on….

StockNews.com

AbbVie Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 10 strange trades.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

5 "Strong Buy" Pharmaceutical Stocks to Own for the Long Haul

The inelastic demand and rising investments in research and development should drive the pharmaceutical industry’s growth in the long run. Therefore, pharmaceutical stocks AbbVie (ABBV), Amgen (AMGN), Catalyst (CPRX), Novo Nordisk (NVO), and Vertex (VRTX), which possess sound fundamentals, could be solid long-term investments. These stocks are rated Strong Buy…

StockNews.com

Check Out What Whales Are Doing With ABBV

Someone with a lot of money to spend has taken a bullish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 6.01% on an annualized basis producing an average annual return of 15.88%. Currently, AbbVie has a market capitalization of $267.24 billion.

Benzinga

AbbVie Whale Trades Spotted

Someone with a lot of money to spend has taken a bearish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

3 Dividend-Paying Healthcare Stocks to Outperform in the Bear Market

The bear market is creating a challenging environment for investors. One place to find outperformance could be high0-quality, healthcare stocks that are paying a dividend. Therefore, investors should consider dividend-paying healthcare stocks like Johnson & Johnson (JNJ), AbbVie Inc. (ABBV), and Unitedhealth Group (UNH). .

StockNews.com

Why AbbVie Stock Is Trading Higher Today

AbbVie Inc (NYSE: ABBV) shares are trading higher Tuesday after the company announced it submitted a supplemental New Drug Application for atogepant to the U.S. Food and Drug Administration to support the preventive treatment of chronic migraine in adults.

Benzinga

5 Dividend Aristocrats To Buy Now

Last week, the Fed raised its benchmark interest rates three-quarters of a percentage point, marking the most aggressive hike since 1994. And with analysts predicting the economy to slip into a recession, we think dividend aristocrats Abbott (ABT), AbbVie (ABBV), Genuine Parts (GPC), Johnson & Johnson (JNJ), and Sysco (SYY)…

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

AbbVie Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 29 strange trades.

StockNews.com

Bargain-Hunting: 3 Mega-Cap Pharmaceutical Stocks to Buy and Hold

Although the heightened market volatility has caused several pharma stocks to slump in price, the sector’s long-term prospects look bright. This sector has been attracting massive investments and could remain in the limelight in the near term. So, we think it should be wise to buy and hold mega-cap pharmaceutical…

Benzinga

AbbVie Whale Trades For June 14

Benzinga

AbbVie - Genmab Present Epcoritamab Data From Lymphoma Trial

AbbVie Inc (NYSE:ABBV) announced primary results from the large B-cell lymphoma (LBCL) expansion cohort in the EPCORE NHL-1 phase 2 trial of epcoritamab. Epcoritamab demonstrated efficacy with durable responses in patients who had previously received at least two prior lines of anti-lymphoma therapy. The study cohort, which included 157 relapsed/refractory LBCL patients, demonstrated…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 5.42% on an annualized basis producing an average annual return of 16.4%. Currently, AbbVie has a market capitalization of $263.04 billion.

Benzinga

Johnson & Johnson-AbbVie Partnered Lymphoma Drug Slows Disease Progression, Data Shows

Johnson & Johnson (NYSE:JNJ) and AbbVie Inc (NYSE:ABBV) announced primary results from the Phase 3 SHINE study of Imbruvica (ibrutinib) plus bendamustine-rituximab (BR) and rituximab maintenance in older patients with newly diagnosed mantle cell lymphoma (MCL). The combination regime significantly reduced the risk of disease progression or death by 25% compared to placebo plus BR…

Benzinga

AbbVie Whale Trades For June 01

A whale with a lot of money to spend has taken a noticeably bullish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 10 strange trades.

Benzinga

If You Invested $1000 In AbbVie 5 Years Ago, Here's How Much You Would Have Today

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 7.1% on an annualized basis producing an average annual return of 17.45%. Currently, AbbVie has a market capitalization of $260.97 billion.

StockNews.com

5 Stalwart Stocks to Load Up on During the Market Sell-Off

Worries about looming recession due to the Fed's tighter monetary policy and other macroeconomic headwinds have kept the stock market under pressure. Amid such a scenario, investing in shares of stalwart companies Intel (INTC), AbbVie (ABBV), FedEx(FDX)), Oracle (ORCL), and The Coca-Cola (KO) could help investors dodge the short-term market…

Benzinga

AbbVie Submits FDA Application For Continuous, 24-Hour Infusion Therapy For Parkinson's

AbbVie Inc (NYSE:ABBV) submitted its FDA marketing application for ABBV-951, a solution of levodopa and carbidopa prodrugs being evaluated in advanced Parkinson’s patients who don’t respond well to oral therapy. AbbVie’s theory here revolves around using a continuous, 24-hour infusion of its therapy. The levodopa and carbidopa prodrugs are delivered in small doses…

Benzinga

AbbVie Whale Trades Spotted

1 … 8 9 10 11

People

Jaimini DesaiJaimini

62 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.